Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside

• Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2.
• The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders.
• This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage.

For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to its late stage portfolio. Narcolepsy treatments remain an area where many patients still face gaps in symptom control and tolerability, so a new orexin 2 agonist candidate may attract attention from both clinicians and investors.

As these Phase 3 trials progress, readers will likely watch for enrollment updates, top line data timing, and how alixorexton might fit within existing narcolepsy treatment options if approved. The outcome of the Brilliance Studies could influence how Alkermes positions NasdaqGS:ALKS within the broader sleep disorder treatment space over time.

Stay updated on the most important news stories for Alkermes by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alkermes.

We've flagged 1 risk for Alkermes. See which could impact your investment.

Quick Assessment

• ✅ Price vs Analyst Target: At US$35.36 vs a consensus target of US$43.71, Alkermes trades about 24% below analyst expectations.
• ✅ Simply Wall St Valuation: The shares are flagged as trading around 66.5% below an estimated fair value.
• ✅ Recent Momentum: The 30 day return of 16.9% shows positive short term price momentum.

There is only one way to know the right time to buy, sell or hold Alkermes. Head to Simply Wall St's company report for the latest analysis of Alkermes's Fair Value.

Key Considerations

• 📊 Phase 3 alixorexton trials add a fresh potential revenue stream to Alkermes' existing neuroscience and psychiatry portfolio.
• 📊 Keep an eye on trial timelines, safety data, and how narcolepsy specialists react to efficacy compared with current standards of care.
• ⚠️ Profit margins of 16.4% are lower than the prior year level of 23.9%, so any R&D setbacks could be felt more in profitability.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Alkermes analysis. Alternatively, you can visit the community page for Alkermes to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com